Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 9 mechanisms across 44 industry trials with a known mechanism of action.

See full pipeline →

Hypoxia-inducible Factor Inhibitor

7 trials 7 active 2 sponsors

Programmed Death Receptor-1 Blocking Antibody

22 trials 2 active 4 sponsors

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

4 trials 2 active 3 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

1 trials 1 active 1 sponsor

Kinase Inhibitor

6 trials 6 sponsors

Lymphocyte Growth Factor

1 trials 1 sponsor

Vascular Endothelial Growth Factor Inhibitor

1 trials 1 sponsor

RANK Ligand Inhibitor

1 trials 1 sponsor

Thalidomide Analog

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

307 industry-sponsored trials across 154 sponsors

View full landscape →

Showing 8 of 8 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-05-11	NCT02982954
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-07-17	NCT03444766
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2018-03-19	NCT02596035
iOMEDICO AG	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2017-09-26	NCT01266837
iOMEDICO AG	Pazopanib	—	COMPLETED	2017-06-30	NCT01521715
Novartis	RAD001	—	COMPLETED	2017-06-06	NCT01206764
Novartis	Everolimus (RAD001)	—	COMPLETED	2016-04-01	NCT01514448
Novartis	Aldesleukin	Lymphocyte Growth Factor [EPC]	COMPLETED	2010-03-28	NCT00414765

Showing 36 of 36 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Telix Pharmaceuticals (Innovations) Pty Limited	89Zr-TLX250 PET/CT	—	RECRUITING	2026-06-30	NCT06750419
Xynomic Pharmaceuticals, Inc.	Pazopanib	—	RECRUITING	2026-12-30	NCT03592472
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	RECRUITING	2027-08-31	NCT07197580
Arcus Biosciences, Inc.	Casdatifan	—	RECRUITING	2028-04	NCT07011719
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	RECRUITING	2032-02-27	NCT07227402
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2027-03-11	NCT03873402
AstraZeneca	Volrustomig	—	ACTIVE NOT RECRUITING	2030-02-21	NCT07000149
Bristol-Myers Squibb	Nivolumab and rHuPH20	—	ACTIVE NOT RECRUITING	2025-07-29	NCT04810078
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2025-07	NCT05678673
AstraZeneca	savolitinib	—	ACTIVE NOT RECRUITING	2025-06-23	NCT05043090
Hutchmed	fruquintinib+sintilimab	—	ACTIVE NOT RECRUITING	2025-01	NCT05522231
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2022-01-31	NCT03937219
Eisai Inc.	Lenvatinib	—	ACTIVE NOT RECRUITING	2020-08-28	NCT02811861
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2020-02-12	NCT03141177
AVEO Pharmaceuticals, Inc.	Tivozanib	—	COMPLETED	2026-01-20	NCT04987203
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	COMPLETED	2022-10-20	NCT03849118
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-12-14	NCT03142334
Roche	Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody	—	COMPLETED	2020-02-14	NCT02420821
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2018-10-18	NCT02853331
Incyte Corporation	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2018-08-22	NCT03260894
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2017-06-26	NCT02231749
Novartis	pazopanib	—	COMPLETED	2015-10-15	NCT01235962
Immatics Biotechnologies GmbH	Sunitinib	—	COMPLETED	2015-07	NCT01265901
Exelixis	Cabozantinib tablets	—	COMPLETED	2015-05-22	NCT01865747
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2015-05-06	NCT01668784
AVEO Pharmaceuticals, Inc.	Tivozanib	—	COMPLETED	2014-07	NCT01076010
Novartis	Dovitinib	—	COMPLETED	2014-06	NCT01223027
AVEO Pharmaceuticals, Inc.	tivozanib (AV-951)	—	COMPLETED	2012-07	NCT01030783
Pfizer	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2012-04	NCT00631371
Heidelberg Pharma AG	124-Iodine-cG250 (124I-cG250)	—	COMPLETED	2009-11	NCT00606632
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	TERMINATED	2022-05-03	NCT03024996
Nektar Therapeutics	bempegaldesleukin	—	TERMINATED	2022-01-07	NCT03729245
Argos Therapeutics	Standard Treatment	—	TERMINATED	2018-04	NCT01582672
Lantheus Medical Imaging	piflufolastat F 18	—	WITHDRAWN	2027-09	NCT07084909
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	WITHDRAWN	2021-08-14	NCT03693573
Heidelberg Pharma AG	Iodine (124I) Girentuximab	—	WITHDRAWN	2018-12-01	NCT01762592

Showing 100 of 120 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
3D Medicines (Sichuan) Co., Ltd.	Lenvatinib + Envafolimab	—	RECRUITING	2026-12	NCT05024214
GI Innovation, Inc.	GI-108	—	RECRUITING	2027-02	NCT07172802
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Beijing Biotech	EB-701/CA9-NK	—	RECRUITING	2027-04-14	NCT07551349
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10516 + Lenvatinib	—	RECRUITING	2027-07-10	NCT07097935
Pfizer	PF-08634404	—	RECRUITING	2027-11-02	NCT07227415
Regeneron	REGN5678	—	RECRUITING	2027-11-15	NCT03972657
Advenchen Pharmaceuticals, LLC.	AL8326 40 mg	—	RECRUITING	2027-12	NCT05363280
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
A2 Biotherapeutics Inc.	A2B395	—	RECRUITING	2029-03-31	NCT06682793
AstraZeneca	AZD6750	—	RECRUITING	2029-10-02	NCT07115043
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2029-11-28	NCT07293351
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068；Adebrelimab ；Bevacizumab	—	RECRUITING	2030-12	NCT07239596
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	RECRUITING	2031-10-26	NCT07049926
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Simcha IL-18, Inc.	ST-067	—	RECRUITING	2025-06-30	NCT04787042
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
Adicet Therapeutics	ADI-270	—	ACTIVE NOT RECRUITING	2026-06	NCT06480565
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-07-21	NCT05468697
Inhibrx Biosciences, Inc	INBRX-106 - Hexavalent OX40 agonist antibody	—	ACTIVE NOT RECRUITING	2026-10-30	NCT04198766
Roche	Tobemstomig	—	ACTIVE NOT RECRUITING	2026-10-31	NCT05805501
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-02-26	NCT03634540
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-04-29	NCT03401788
Sensei Biotherapeutics, Inc.	SNS-101 (anti-VISTA)	—	ACTIVE NOT RECRUITING	2027-06	NCT05864144
Merck	Intismeran autogene	—	ACTIVE NOT RECRUITING	2028-01-08	NCT06307431
ImmunityBio, Inc.	N-803 + Pembrolizumab	—	ACTIVE NOT RECRUITING	2029-08-31	NCT03228667
Roche	Entrectinib	ALK/ROS1/NTRK1/TRKB/TRKC	ACTIVE NOT RECRUITING	2026-05-14	NCT02568267
Arsenal Biosciences, Inc.	AB-2100	—	ACTIVE NOT RECRUITING	2026-03-31	NCT06245915
Akeso	AK104	—	ACTIVE NOT RECRUITING	2025-12-31	NCT05256472
Beijing Scitech-Mq Pharmaceuticals Limited	ST-1898 tablets	—	ACTIVE NOT RECRUITING	2025-12	NCT06127238
Salubris Biotherapeutics Inc	JK08	—	ACTIVE NOT RECRUITING	2025-10-17	NCT05620134
Vyriad, Inc.	VSV-IFNβ-NIS	—	ACTIVE NOT RECRUITING	2025-07-31	NCT03647163
ImaginAb, Inc.	zirconium Zr 89 crefmirlimab berdoxam	—	ACTIVE NOT RECRUITING	2025-07	NCT05013099
BeiGene	BGB-A445	—	ACTIVE NOT RECRUITING	2025-05-27	NCT05661955
Merck	Pembrolizumab (+) Berahyaluronidase alfa	—	ACTIVE NOT RECRUITING	2025-04-09	NCT06099782
23andMe, Inc.	23ME-00610	—	ACTIVE NOT RECRUITING	2025-03	NCT05199272
Nimbus Saturn, Inc.	NDI-101150	—	ACTIVE NOT RECRUITING	2025-02	NCT05128487
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
SillaJen, Inc.	Pexastimogene Devacirepvec (Pexa-Vec)	—	ACTIVE NOT RECRUITING	2023-08	NCT03294083
Imbioray (Hangzhou) Biomedicine Co., Ltd.	IBR854	—	NOT YET RECRUITING	2026-12-31	NCT07087158
Regeneron	REGN15505	—	NOT YET RECRUITING	2030-09-20	NCT07594106
CRISPR Therapeutics AG	CTX131	—	COMPLETED	2025-09-18	NCT05795595
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2025-01-27	NCT04704219
Norroy Bioscience Co., LTD	68Ga-NYM005 injection	—	COMPLETED	2025-01-08	NCT06389682
HUYABIO International, LLC.	HBI-8000 in combination with nivolumab	—	COMPLETED	2023-09	NCT02718066
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	MK-3795	—	COMPLETED	2023-08-30	NCT03108066
Ipsen	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	COMPLETED	2023-05-11	NCT03945773
Nektar Therapeutics	Dose Escalation Doublet: Combination of NKTR-214 + nivolumab	—	COMPLETED	2022-04-28	NCT02983045
X4 Pharmaceuticals	X4P-001	—	COMPLETED	2022-04-14	NCT02667886
Genocea Biosciences, Inc.	GEN-009 Adjuvanted Vaccine	—	COMPLETED	2021-12-08	NCT03633110
Eisai Inc.	lenvatinib	—	COMPLETED	2021-11-02	NCT02915783
Pharmacyclics LLC.	ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2021-08-20	NCT02599324
Novartis	Pazopanib	—	COMPLETED	2021-08-10	NCT03200717
Incyte Corporation	Retifanlimab	—	COMPLETED	2021-04-15	NCT03679767
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-04-01	NCT02089685
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-02-05	NCT02853344
Mendus	Intuvax (INN: ilixadencel)	—	COMPLETED	2021-01-31	NCT02432846
Astellas Pharma Global Development, Inc.	AGS-16C3F	—	COMPLETED	2020-10-02	NCT02639182
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2020-08-31	NCT03428217
Takeda	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	COMPLETED	2020-08-25	NCT03339219
Mirati Therapeutics Inc.	Sitravatinib	—	COMPLETED	2020-04-27	NCT03680521
MedImmune LLC	MEDI0680	—	COMPLETED	2020-03-17	NCT02118337
Eisai Inc.	lenvatinib	—	COMPLETED	2020-02-14	NCT03173560
Millennium Pharmaceuticals, Inc.	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2020-02-03	NCT02724020
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2019-04-26	NCT03163667
Celldex Therapeutics	Combination of varlilumab and nivolumab	—	COMPLETED	2018-12-12	NCT02335918
Incyte Corporation	MK-3475	—	COMPLETED	2018-11-26	NCT02178722
Eli Lilly	Emibetuzumab	—	COMPLETED	2017-12-05	NCT02082210
Bristol-Myers Squibb	Opdivo	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2017-11-27	NCT03029780
GenSpera, Inc.	G-202	—	COMPLETED	2016-12	NCT02607553
Roche	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody	—	COMPLETED	2016-10-17	NCT01984242
NewLink Genetics Corporation	CRLX101	—	COMPLETED	2016-07	NCT02187302
Novartis	everolimus	Kinase Inhibitor [EPC]	COMPLETED	2015-05	NCT00903175
Novartis	RAD001	—	COMPLETED	2015-05	NCT01491672
Taiwan Liposome Company	Lipotecan	—	COMPLETED	2015-03-19	NCT01831973
Eisai Inc.	Lenvatinib	—	COMPLETED	2014-06-13	NCT01136733
Intuitive Surgical	—	—	COMPLETED	2013-10	NCT02136121
Bristol-Myers Squibb	nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2013-05-15	NCT01354431
Roche	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2013-05	NCT01442090
AVEO Pharmaceuticals, Inc.	Tivozanib	—	COMPLETED	2012-10	NCT01297244
Amgen	denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2012-09-13	NCT00896454
Argos Therapeutics	AGS-003	—	COMPLETED	2012-05	NCT00678119
GE Healthcare	Fluciclatide Injection	—	COMPLETED	2011-09	NCT00918281
Amgen	Sunitinib	—	COMPLETED	2011-08-08	NCT00853372
Eli Lilly	Enzastaurin	—	COMPLETED	2010-02-15	NCT00709995
Ocellaris Pharma, Inc.	OC-001	—	TERMINATED	2025-11-07	NCT04260802
Genmab	GEN1160	—	TERMINATED	2025-11-05	NCT05721222
NiKang Therapeutics, Inc.	Oral NKT2152	—	TERMINATED	2025-08-22	NCT05119335
NiKang Therapeutics, Inc.	NKT2152	—	TERMINATED	2025-06-30	NCT05935748
Takeda	TAK-500	—	TERMINATED	2025-01-06	NCT05070247
Kymab Limited	Alomfilimab	—	TERMINATED	2024-10-03	NCT03829501
ImaginAb, Inc.	Zirconium 89Zr crefmirlimab berdoxam	—	TERMINATED	2024-05-31	NCT05744128
Incyte Corporation	INCB086550	—	TERMINATED	2024-03-26	NCT04629339
Elevation Oncology	Seribantumab	—	TERMINATED	2024-02-28	NCT04383210
CoImmune	CMN-001	—	TERMINATED	2023-09-28	NCT04203901
Aravive, Inc.	Batiraxcept	—	TERMINATED	2023-08-14	NCT04300140
4D pharma plc	MRx0518	—	TERMINATED	2023-05-08	NCT03637803
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	TERMINATED	2022-10-19	NCT03311334

Showing 100 of 143 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jemincare	JMKX003948	—	RECRUITING	2026-05-31	NCT06321250
SAPU NANO (US) LLC	Sapu003	—	RECRUITING	2026-06	NCT07369505
Jiangsu Hansoh Pharmaceutical Co., Ltd.	Oral HS-10516	—	RECRUITING	2026-07-31	NCT06553339
Osel, Inc.	CBM588 Capsules	—	RECRUITING	2026-10-19	NCT06399419
HiberCell, Inc.	HC-7366	—	RECRUITING	2026-11	NCT06234605
Kura Oncology, Inc.	Darlifarnib	—	RECRUITING	2027-01	NCT06026410
Neomorph, Inc	NEO-811	—	RECRUITING	2027-01	NCT07300241
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Xencor, Inc.	XmAb819	—	RECRUITING	2027-02	NCT05433142
Shanghai Henlius Biotech	HLX17	—	RECRUITING	2027-04-30	NCT07160335
Novelty Nobility, Inc.	NN3201	—	RECRUITING	2027-08-30	NCT06805825
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
LG Chem	Phase 1a: LB-LR1109	—	RECRUITING	2027-11	NCT06332755
Grit Biotechnology	IB-T101 injection	—	RECRUITING	2027-12-07	NCT06819293
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
Chongqing Precision Biotech Co., Ltd	CD70-targeted CAR-T cells	—	RECRUITING	2028-03-31	NCT07181720
Compass Therapeutics	CTX-10726	—	RECRUITING	2028-04-01	NCT07419841
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
AstraZeneca	FPI-2053	—	RECRUITING	2028-05-12	NCT06147037
Deciphera Pharmaceuticals, LLC	DCC-2812	—	RECRUITING	2029-02	NCT06966024
Arcus Biosciences, Inc.	casdatifan	—	RECRUITING	2029-03	NCT05536141
Bristol-Myers Squibb	BMS-986506	—	RECRUITING	2030-05-03	NCT07195682
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
Janux Therapeutics	JANX008	—	RECRUITING	2026-01	NCT05783622
Chongqing Precision Biotech Co., Ltd	CD70 CAR-T cells	—	RECRUITING	2025-12-31	NCT06010875
Molecure S.A.	OATD-02	—	RECRUITING	2025-12	NCT05759923
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	RECRUITING	2024-12	NCT05868174
Toray Industries, Inc	TRK-950	—	ACTIVE NOT RECRUITING	2026-06	NCT03872947
OncoC4, Inc.	AI-061	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05858736
Asher Biotherapeutics, Inc.	etakafusp alfa (AB248)	—	ACTIVE NOT RECRUITING	2026-08	NCT05653882
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
HiFiBiO Therapeutics	HFB200301	—	ACTIVE NOT RECRUITING	2026-12	NCT05238883
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
Nanobiotix	NBTXR3	—	ACTIVE NOT RECRUITING	2027-04-30	NCT03589339
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-06-30	NCT05030506
Daiichi Sankyo	DS-6000a	—	ACTIVE NOT RECRUITING	2026-04-30	NCT04707248
Poseida Therapeutics, Inc.	P-MUC1C-ALLO1 CAR-T cells	—	ACTIVE NOT RECRUITING	2026-04	NCT05239143
Arcus Biosciences, Inc.	AB598	—	ACTIVE NOT RECRUITING	2026-03	NCT05891171
HiFiBiO Therapeutics	HFB200603	—	ACTIVE NOT RECRUITING	2025-12	NCT05789069
Allogene Therapeutics	ALLO-647	—	ACTIVE NOT RECRUITING	2025-10	NCT04696731
MedImmune LLC	MEDI5752	—	ACTIVE NOT RECRUITING	2025-09-26	NCT04522323
DEKA Biosciences	DK210 (EGFR)	—	ACTIVE NOT RECRUITING	2025-07	NCT05704985
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
RemeGen Co., Ltd.	RC198 Injection	—	ACTIVE NOT RECRUITING	2024-09-30	NCT05867303
Biomica Ltd.	BMC128	—	ACTIVE NOT RECRUITING	2024-05	NCT05354102
Exelixis	cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2023-02-21	NCT03170960
Checkpoint Therapeutics, Inc.	CK-301 (cosibelimab)	—	ACTIVE NOT RECRUITING	2021-11-18	NCT03212404
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2018-01-12	NCT02974738
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	MK-3795	—	ACTIVE NOT RECRUITING	2017-01-31	NCT02293980
AccSalus Biosciences, Inc.	ACC-1898	—	NOT YET RECRUITING	2027-06	NCT07252661
Mabpro, a.s.	CA9hu-1	—	NOT YET RECRUITING	2026-01	NCT05698238
Philogen S.p.A.	[68Ga]Ga-OncoCAIX	—	COMPLETED	2025-11-28	NCT06840548
MacroGenics	vobramitamab duocarmazine	—	COMPLETED	2025-06-24	NCT05293496
Coherus Oncology, Inc.	CHS-388	—	COMPLETED	2025-05-28	NCT04374877
Celldex Therapeutics	CDX-585	—	COMPLETED	2025-05-21	NCT05788484
Xencor, Inc.	XmAb®808	—	COMPLETED	2025-05-20	NCT05585034
Xencor, Inc.	XmAb®23104	—	COMPLETED	2024-02-15	NCT03752398
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-01-18	NCT04540705
HiberCell, Inc.	HC-5404-FU	—	COMPLETED	2023-12-07	NCT04834778
Telix Pharmaceuticals (Innovations) Pty Limited	89Zr-Girentuximab	—	COMPLETED	2023-11-27	NCT05861778
Mirati Therapeutics Inc.	Sitravatinib	—	COMPLETED	2023-06-30	NCT04518046
Shattuck Labs, Inc.	SL-279252	—	COMPLETED	2023-05-04	NCT03894618
Celldex Therapeutics	CDX-527	—	COMPLETED	2023-04-06	NCT04440943
Novartis	Gevokizumab	—	COMPLETED	2023-03-01	NCT03798626
Xencor, Inc.	XmAb®22841	—	COMPLETED	2023-02-16	NCT03849469
Fate Therapeutics	FT500	—	COMPLETED	2022-11-15	NCT03841110
Quadriga Biosciences, Inc.	QBS10072S	—	COMPLETED	2022-09-21	NCT04430842
Celldex Therapeutics	CDX-1140	—	COMPLETED	2022-09-13	NCT03329950
Tempest Therapeutics	Part 1 TPST-1120	—	COMPLETED	2022-09-07	NCT03829436
Xencor, Inc.	XmAb20717	—	COMPLETED	2022-06-01	NCT03517488
Arrowhead Pharmaceuticals	ARO-HIF2	—	COMPLETED	2022-01-24	NCT04169711
Arcus Biosciences, Inc.	Etrumadenant	—	COMPLETED	2021-08-18	NCT03629756
Incyte Corporation	INCAGN02390	—	COMPLETED	2021-08-18	NCT03652077
Evelo Biosciences, Inc.	EDP1503	—	COMPLETED	2021-06-30	NCT03775850
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-06-14	NCT03063762
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	COMPLETED	2020-10-27	NCT04496089
Incyte Biosciences International Sàrl	INCAGN02385	—	COMPLETED	2020-10-07	NCT03538028
Fate Therapeutics	FATE-NK100	—	COMPLETED	2020-05-29	NCT03319459
Incyte Corporation	INCB001158	—	COMPLETED	2020-04-30	NCT02903914
Five Prime Therapeutics, Inc.	Cabiralizumab	—	COMPLETED	2019-11-18	NCT02526017
Incyte Corporation	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-11-07	NCT02646748
MacroGenics	MGA271	—	COMPLETED	2019-04-18	NCT01391143
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2019-03	NCT02071862
Eli Lilly	Pegilodecakin	—	COMPLETED	2019-02-19	NCT02009449
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Sunitinib malate capsules generic product	—	COMPLETED	2019-01-06	NCT05800106
Cancer Targeted Technology	CTT1057	—	COMPLETED	2018-08-31	NCT03427476
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	COMPLETED	2018-08	NCT02498665
Bristol-Myers Squibb	CC-486	—	COMPLETED	2018-06-11	NCT02223052
Pfizer	Axitinib	Kinase Inhibitor [EPC]	COMPLETED	2017-03-31	NCT02133742
Agensys, Inc.	AGS-16C3F	—	COMPLETED	2017-02-21	NCT01672775
Seagen Inc.	SGN-CD70A	—	COMPLETED	2017-02-15	NCT02216890
NewLink Genetics Corporation	HyperAcute®-Renal (HAR) Immunotherapy	—	COMPLETED	2017-01-03	NCT02035358
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2016-02-02	NCT01472081
Akamis Bio	Colo-Ad1	—	COMPLETED	2015-04	NCT02053220
Novartis	RAD001 + BEZ235	—	COMPLETED	2015-02	NCT01482156
Bristol-Myers Squibb	BMS-936558 (Anti-PD-1)	—	COMPLETED	2014-12-01	NCT01358721
Amgen	AMG 172	—	COMPLETED	2014-11	NCT01497821
Novartis	Everolimus (RAD001)	—	COMPLETED	2013-12	NCT01152801
Mendus	Combig-DC (allogeneic dendritic cells) Cancer Vaccine	—	COMPLETED	2013-12	NCT01525017
Bristol-Myers Squibb	BMS-936558 (MDX-1106)	—	COMPLETED	2013-02-04	NCT00730639

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Renal Cell Carcinoma

VEGF (17) RET (14) ROS1 (11) PD-1 (11) FLT3 (10) MET (10)

Novel Drugs by Company (New molecular entities)

Merck 2 drugs

Bristol-Myers Squibb 1 drug

CHIRON 1 drug

AVEO PHARMS 1 drug

TIVOZANIB HYDROCHLORIDE

NDA 2021

Reformulations (7 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

BIO-THERA SOLUTIONS LTD